Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02ALD
|
||||
| Former ID |
DIB001242
|
||||
| Drug Name |
NOLOMIROLE HYDROCHLORIDE
|
||||
| Synonyms |
CHF-1035; Nolomirole hydrochloride < Prop INNM >; Rac-5,6-Diisobutyryloxy-2-(methylamino)-1,2,3,4-tetrahydronaphthalene hydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Heart failure [ICD9: 428; ICD10:I50] | Discontinued in Phase 3 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H28ClNO4
|
||||
| Canonical SMILES |
CC(C)C(=O)OC1=C(C2=C(CC(CC2)NC)C=C1)OC(=O)C(C)C.Cl
|
||||
| InChI |
1S/C19H27NO4.ClH/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4;/h6,9,11-12,14,20H,7-8,10H2,1-5H3;1H
|
||||
| InChIKey |
TWTMQRXNAZGSCE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [2] | |
| D(2) dopamine receptor | Target Info | Agonist | [2], [3] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04015:Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolismR-HSA-390651:Dopamine receptors | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003364) | ||||
| REF 2 | Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan;49(1):1-5. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.